Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting conjunctivitis and keratitis, thyroid eye disease (TED), and uveitis. 1 ...
Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...
LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...
SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...
At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.
Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...
David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results